시장보고서
상품코드
1770771

트라코마 치료제 시장 규모, 점유율, 성장 분석 : 치료별, 약물 종류별, 투여 경로별, 연령별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)

Trachoma Treatment Market Size, Share, and Growth Analysis, By Treatment (Medication, Surgery), By Drug Class (Macrolides, Tetracycline), By Route of Administration, By Age-group, By Distribution Channel, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 188 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

트라코마 치료제 세계 시장 규모는 2023년에 5억 3,020만 달러로 평가되었으며, 예측 기간(2025-2032년) 동안 CAGR 7.1%로, 2024년 5억 6,784만 달러에서 2032년에는 9억 8,298만 달러로 성장할 전망입니다.

트라코마 치료제 시장은 아프리카, 아시아, 라틴아메리카를 중심으로 한 신흥국 지역의 높은 유병률에 힘입어 크게 성장하고 있습니다. 정부의 노력과 국제적인 자금 지원의 증가로 집단 투약과 공중보건 캠페인을 통한 퇴치 활동이 가속화되고 있습니다. 아지트로마이신과 같은 항생제에 대한 접근성이 향상되고, 종종 기부 프로그램을 통해 제공되면서 치료 효과를 더욱 높이고 있습니다. 또한, 인식 개선과 위생 교육 노력은 예방과 재감염률을 낮추는데 중요한 역할을 하고 있습니다. 하지만, 열악한 의료 인프라, 열악한 위생 환경, 기부자 지원에 대한 의존도, 특정 집단의 낮은 인식 등의 문제로 인해 원격지에서의 적시 치료와 지속적인 질병 퇴치 활동을 방해하고 있습니다. 이러한 문제를 해결하는 것이 지속적인 시장 확대에 필수적입니다.

목차

소개

  • 조사 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차와 1차 데이터 방법
  • 시장 규모 예측
  • 시장 가정과 제한

주요 요약

  • 세계 시장 전망
  • 공급과 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porters 분석

주요 시장 인사이트

  • 핵심성공요인
  • 경쟁 정도
  • 주요 투자 기회
  • 시장 생태계
  • 시장 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석
  • 기술 분석
  • 사례 연구
  • 규제 분석

트라코마 치료제 시장 규모 : 치료별 & CAGR(2025-2032년)

  • 시장 개요
  • 수술
  • 기타

트라코마 치료제 시장 규모 : 약물 종류별 & CAGR(2025-2032년)

  • 시장 개요
  • 매크로라이드
  • 테트라사이클린
  • 안과용 항감염제
  • 설폰아미드

트라코마 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032년)

  • 시장 개요
  • 경구
  • 외용

트라코마 치료제 시장 규모 : 연령별 & CAGR(2025-2032년)

  • 시장 개요
  • 아동
  • 성인
  • 노인

트라코마 치료제 시장 규모 : 유통 채널별 & CAGR(2025-2032년)

  • 시장 개요
  • 병원 약국
  • 소매 약국
  • 온라인 약국

트라코마 치료제 시장 규모 : 지역별 & CAGR(2025-2032년)

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5개사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채용한 전략
  • 최근의 시장 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업 개요
    • 기업 상세
    • 제품 포트폴리오 분석
    • 기업 부문별 점유율 분석
    • 매출 전년비 비교(2022-2024년)

주요 기업 개요

  • F. Hoffmann-La Roche Ltd.(Switzerland)
  • Mylan N.V.(US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi(France)
  • Pfizer Inc.(US)
  • GlaxoSmithKline plc(UK)
  • Novartis AG(Switzerland)
  • Bayer AG(Germany)
  • Eli Lilly and Company(US)
  • Merck & Co., Inc.(US)
  • Allergan(Ireland)
  • AstraZeneca(UK)
  • AbbVie Inc.(US)
  • Johnson & Johnson Private Limited(US)
  • Cipla Inc.(US)
  • Bausch Health Companies Inc.(Canada)
  • Abbott(US)
  • Fresenius Kabi AG(Germany)

결론과 제안

ksm 25.07.21

Global Trachoma Treatment Market size was valued at USD 530.2 million in 2023 and is poised to grow from USD 567.84 million in 2024 to USD 982.98 million by 2032, growing at a CAGR of 7.1% during the forecast period (2025-2032).

The trachoma treatment market is experiencing significant growth, driven by the high prevalence of the disease in developing regions, especially Africa, Asia, and Latin America. Increased government initiatives and international funding have accelerated eradication efforts through mass medication and public health campaigns. Improved access to antibiotics like azithromycin, often provided through donation programs, further supports treatment availability. Moreover, rising awareness and hygiene education initiatives play a vital role in prevention and reducing reinfection rates. However, challenges such as inadequate healthcare infrastructure, poor sanitation, reliance on donor aid, and low awareness in certain populations hinder timely treatment and ongoing disease control efforts in remote areas. Addressing these issues is crucial for sustained market advancement.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Trachoma Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Trachoma Treatment Market Segments Analysis

Global Trachoma Treatment Market is segmented by Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel and region. Based on Treatment, the market is segmented into Medication, Surgery and Others. Based on Drug Class, the market is segmented into Macrolides, Tetracycline, Ophthalmic anti-infective and Sulfonamides. Based on Route of Administration, the market is segmented into Oral and Topical. Based on Age-group, the market is segmented into Children, Adults and Geriatric. Based on Distribution Channel, the market is segmented into Hospital pharmacy, Retail pharmacy and Online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Trachoma Treatment Market

The Global Trachoma Treatment market is significantly driven by the high prevalence of trachoma in many developing countries, especially in certain areas of Africa and Asia. Factors such as overcrowded living conditions, poor sanitation, and limited access to clean water exacerbate the issue, leading to a continual need for effective treatment options. This ongoing health challenge necessitates the implementation of extensive intervention programs, which in turn amplifies the demand for trachoma treatment products across these regions. As a result, the intersection of these elements plays a crucial role in propelling the growth and penetration of the treatment market globally.

Restraints in the Global Trachoma Treatment Market

The global trachoma treatment market faces significant constraints due to the inadequate healthcare infrastructure prevalent in many trachoma-endemic regions. This poor infrastructure hampers crucial aspects like diagnosis, treatment implementation, and patient follow-up. A lack of trained healthcare personnel, substandard medical facilities, and ineffective logistical systems greatly hinder the execution of mass treatment initiatives. Such barriers delay the delivery of interventions, reduce the coverage of treatment efforts, and diminish the effectiveness of public health campaigns aimed at eradicating the disease. Consequently, these factors collectively restrain the overall growth and development of the trachoma treatment market on a global scale.

Market Trends of the Global Trachoma Treatment Market

The Global Trachoma Treatment market is witnessing a transformative trend driven by AI-driven mobile diagnostics, which promise to redefine early detection and screening practices. These innovative, technology-enhanced applications are pivotal in suburban and under-resourced areas, streamlining the process of diagnosing trachoma while reducing dependency on specialized ophthalmic professionals. Consequently, this advancement enables extensive population screenings, enhancing both treatment accuracy and accessibility. As a result, healthcare systems can leverage real-time data analytics for improved surveillance models and informed decision-making, ultimately leading to more effective and efficient management of trachoma on a global scale. This trend signals significant growth potential in the market.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technology Analysis
  • Case Studies
  • Regulatory Analysis

Global Trachoma Treatment Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Medication
  • Surgery
  • Others

Global Trachoma Treatment Market Size by Drug Class & CAGR (2025-2032)

  • Market Overview
  • Macrolides
  • Tetracycline
  • Ophthalmic anti-infective
  • Sulfonamides

Global Trachoma Treatment Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Oral
  • Topical

Global Trachoma Treatment Market Size by Age-group & CAGR (2025-2032)

  • Market Overview
  • Children
  • Adults
  • Geriatric

Global Trachoma Treatment Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

Global Trachoma Treatment Market Size & CAGR (2025-2032)

  • North America (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • US
    • Canada
  • Europe (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson Private Limited (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cipla Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bausch Health Companies Inc. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius Kabi AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제